Gendux AB, of Stockholm, Sweden, submitted an orphan drug designation request to the European Medicines Evaluation Agency for the use of Advexin p53 therapy in cancer patients with Li-Fraumeni syndrome

Advaxis Inc., of North Brunswick, N.J., said the first cancer patients to be treated with an engineered live Listeria vaccine recently were dosed in the company's Phase I/II clinical trial of Lovaxin C, a Listeria-based therapeutic cancer vaccine developed to treat cervical cancer...The trial, taking place in Serbia, Israel and Mexico, will enroll 20 cervical cancer patients and is expected to last about six months

OncoGenex Technologies Inc., of Vancouver, British Columbia, said Phase I results showed the one-year survival rate to be 67 percent for the nine non-small-cell lung cancer patients who received at least one dose of OGX-011 in combination with chemotherapy

The trial is expected to enroll about 20 cervical cancer patients and last about six months, with safety as its primary objective...EntreMed Inc., of Rockville, Md., began a Phase I trial to evaluate the safety, tolerability, pharmacokinetics and clinical benefit of its new tubulin-binding agent, ENMD-1198, in advanced cancer patients

Prostate cancer patients in the ADT trial who have completed the full two-year treatment will be eligible for an additional year of treatment with the extension trial

It will enroll up to 20 breast cancer patients who have undergone a partial mastectomy

The study is designed to monitor the safety and efficacy of its compound in cancer patients undergoing chemotherapy and suffering from anemia

ArQule Inc., of Woburn, Mass., said Phase I data of ARQ 501 showed evidence of clinical tolerability and antitumor activity in cancer patients with advanced solid tumors who had failed prior treatments with chemotherapy...SNS-595 is in two Phase II studies in non-small-cell lung cancer and small-cell lung cancer patients, as well as a Phase I dose-escalation study in patients with acute leukemias

It has enrolled 122 cancer patients on maintenance opioid therapy for persistent pain

Cytokinetics Inc., of South San Francisco, said its partner GlaxoSmithKline plc, of London, will not move to the next stage of a Phase II trial after a planned interim analysis of ispinesib to treat platinum-sensitive non-small-cell lung cancer patients did not satisfy the criteria for advancement

Pro-Pharmaceuticals Inc., of Newton, Mass., completed patient enrollment in Stage I of its Simon Two-Stage-designed Phase II trial for third- and fourth-line treatment of colorectal cancer patients...Shares of ViroPharma jumped nearly 9 percent on the results, and the stock (NASDAQ:VPHM) closed at $12.79 Thursday, up $1.10.

Micromet AG, of Munich, Germany, said data published in a recent issue of Molecular Immunology explained the need for large amounts of antibodies to achieve a therapeutic effect in cancer patients

The company expects to start a new Phase I/II trial in carcinoid cancer patients with advanced tumors in the next few months...The company recently completed the Phase II trial in head and neck cancer patients who demonstrated a 29 percent lower incidence of WHO Grade 3 or greater oral mucositis, or a 46 percent lower incidence of NCI Grade 3 or greater oral mucositis, when taking RK-0202 vs. placebo

Algeta ASA, of Oslo, Norway, said an analysis of the biomarker data from a Phase II trial of its lead product Alpharadin (radium-223) continues to demonstrate its potential as a treatment for bone metastases in hormone-refractory prostate cancer patients (HRPC

Norwood Abbey Ltd., of Melbourne, Australia, said its subsidiary, Norwood Immunology Ltd., began a Phase II trial in cancer patients undergoing autologous bone marrow transplant

INGN 225 also is being testing in a Phase I/II trial in breast cancer patients

Ariad Pharmaceuticals Inc., of Cambridge, Mass., started enrollment of 60 advanced cancer patients in a Phase Ib trial of its novel mTOR inhibitor, AP23573, in combination with doxorubicin

The study will test the drug’s safety and efficacy in up to 30 cancer patients undergoing chemotherapy and suffering from anemia

The trial, being conducted under a special protocol assessment with the FDA, has enrolled 250 pancreatic cancer patients who had received prior treatment with gemcitabine